Dr. Arimoto began his career in research at Eisai Co., Ltd., where he was responsible for the development and regulatory approval of donepezil, leading the team for nine years. He then joined Asahi Kasei Pharma Corporation, serving as Head of Development and Regulatory Affairs, Head of Overseas Clinical Development, and later as Head of Clinical Planning, overseeing and coordinating all development pipelines. He subsequently served as President of Asahi Kasei Group’s overseas subsidiaries for three and a half years. He holds a B.A. from Kyoto University and a Ph.D. in Pharmaceutical Sciences from the Graduate School of Pharmaceutical Sciences, Kyoto University.

(Associate Professor, Graduate School of Pharmaceutical Sciences, Tohoku University)
Dr. Moriguchi began his dementia research during his study abroad at Northwestern University (USA, 2001-2004). After joining Tohoku University as a faculty member in 2004, he focused on calcium signaling in neurons, engaging in dementia drug discovery research and elucidating the disease mechanisms of cognitive and psychiatric disorders. In 2022, he founded Neusignal Therapeutics, Inc. to accelerate the development of novel dementia therapeutics. He holds a Ph.D. in Pharmaceutical Sciences from the Graduate School of Pharmaceutical Sciences, Kyushu University.

At Daiichi Sankyo Company, Limited, Dr. Uno was initially involved in exploratory research, including target molecule identification, lead compound discovery, and mechanistic analysis. She then transitioned to Global Regulatory Affairs, gaining experience in IND/CTA/CTN and NDA/MAA submissions in Japan, the U.S., and Europe. Later, she served as a Global Project Leader in Clinical Development, and managed and oversaw domestic medical strategy planning and execution in Medical Affairs. She holds a B.A. from University of Tokyo and a Ph.D. in Science from the Graduate School of Science, University of Tokyo.